Sulfonylurea
Glibenclamide
GLIBENCLAMIDE
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-1.40 to 0.39) | 0.24 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.52 (-1.51 to 0.79) | 0.31 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.67 (-1.59 to 1.10) | 0.27 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.71 (-1.75 to 1.07) | 0.28 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.94 (-1.23 to 9.93) | 0.11 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 3.06 (-1.20 to 10.23) | 0.09 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.31 (-2.01 to 9.32) | 0.11 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.37 (-2.15 to 10.24) | 0.11 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.31 (0.00 to 23.20) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.40 (0.00 to 28.49) | 0.45 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.06 (0.40 to 2.68) | 0.46 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.10 (0.51 to 2.37) | 0.44 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.42 (0.07 to 1.93) | 0.87 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.79 (0.12 to 3.52) | 0.65 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.89 (0.34 to 2.19) | 0.73 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.19 (0.47 to 2.82) | 0.56 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.07 (0.36 to 2.99) | 0.64 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.11 (0.40 to 2.79) | 0.55 |